Quick Answer
BioXcel Therapeutics, Inc. reported Stockholders Equity of -$95.46 million for the year ending 2025.
- BioXcel Therapeutics, Inc. showed a decrease of -2.5% in Stockholders Equity from 2024 to 2025.
- This data is from BioXcel Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2017 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $52.11 million | Q2 2018: $49.82 million | Q3 2018: $45.82 million | Q1 2019: $32.37 million | Q2 2019: $25.16 million | Q3 2019: $34.42 million | Q1 2020: $72.59 million | Q2 2020: $53.39 million | Q3 2020: $220.94 million | Q1 2021: $186.74 million | Q2 2021: $267.41 million | Q3 2021: $245.56 million | Q1 2022: $194.02 million | Q2 2022: $164.26 million | Q3 2022: $126.99 million | Q1 2023: $53.01 million | Q2 2023: $5.86 million | Q3 2023: -$40.61 million | Q1 2024: -$72.36 million | Q2 2024: -$74.30 million | Q3 2024: -$85.63 million | Q1 2025: -$90.17 million | Q2 2025: -$107.67 million | Q3 2025: -$88.92 million.
- Over the full 10 years of available data (2017 to 2025), BioXcel Therapeutics, Inc.'s Stockholders Equity has declined by 30,302.2%.
- Historical annual values: Fiscal year 2025: -$95.46 million | Fiscal year 2024: -$93.10 million | Fiscal year 2023: -$56.51 million | Fiscal year 2022: $76.78 million | Fiscal year 2021: $221.67 million | Fiscal year 2020: $206.70 million | Fiscal year 2019: $26.90 million | Fiscal year 2018: $38.89 million | Fiscal year 2017: -$982.0 thousand | Fiscal year 2017: -$314.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: